A better understanding of the molecular tumour biology, HER2 pathway and the mechanism of resistance to trastuzumab has enabled the development of novel drugs such as monoclonal antibodies, small molecule tyrosine kinase inhibitors and antibody-drug conjugates that may overcome this resistance. Here, ERBB2 is linked to neoplasm.